Compare Gold Fields Limited (GFI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Sana Biotechnology Inc — how do they compare? Gold Fields Limited trades at $36.82 (market cap $31.87B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Gold Fields Limited is far larger — about 38.1× Sana Biotechnology Inc's market cap, and Gold Fields Limited pays a 6% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Sana Biotechnology Inc for 23 Days on average.
| GFI | SANA | |
|---|---|---|
Market Cap | $31.87B | $836.71M |
Volume | 4,169,651 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $5.92 |
52-Week Low | $31.25 | $2.68 |
Typical Hold Time | 49 Days | 23 Days |
Enterprise Value | $32.47B | $749.96M |
Dividend Yield | 6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $36.82, up 5.05% today, amid mixed technical signals with a bearish overall trend. Fundamentally, the company shows strong profitability with 38.66% net margins and robust cash flow generation of $3.77B from operations in 2025. Recent news highlights the rejected $27B Northern Star takeover bid and strong operational performance from Salares Norte, driving investor attention to the company's capital allocation strategy.
The investment outlook balances strong fundamentals against acquisition risks and technical weakness. With 44% analyst buy ratings and a $52.75 price target suggesting 43% upside, GFI presents value opportunity, though recent earnings misses and bearish technicals warrant caution. Key risks include execution on growth projects and gold price volatility.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
